Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. More Details
Fair value with moderate growth potential.
Share Price & News
How has Teva Pharmaceutical Industries's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TEVA's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: TEVA exceeded the US Pharmaceuticals industry which returned 11.1% over the past year.
Return vs Market: TEVA exceeded the US Market which returned 12.8% over the past year.
Price Volatility Vs. Market
How volatile is Teva Pharmaceutical Industries's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StHow Much Did Teva Pharmaceutical Industries'(NYSE:TEVA) Shareholders Earn From Share Price Movements Over The Last Five Years?
1 month ago | Simply Wall StWhat Did Teva Pharmaceutical Industries' (NYSE:TEVA) CEO Take Home Last Year?
2 months ago | Simply Wall StTeva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet
Is Teva Pharmaceutical Industries undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: TEVA ($9.48) is trading below our estimate of fair value ($29.8)
Significantly Below Fair Value: TEVA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: TEVA is poor value based on its PE Ratio (2590.9x) compared to the US Pharmaceuticals industry average (25x).
PE vs Market: TEVA is poor value based on its PE Ratio (2590.9x) compared to the US market (18.2x).
Price to Earnings Growth Ratio
PEG Ratio: TEVA is poor value based on its PEG Ratio (52.3x)
Price to Book Ratio
PB vs Industry: TEVA is good value based on its PB Ratio (0.7x) compared to the US Pharmaceuticals industry average (3.2x).
How is Teva Pharmaceutical Industries forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TEVA's forecast earnings growth (49.5% per year) is above the savings rate (2.2%).
Earnings vs Market: TEVA's earnings (49.5% per year) are forecast to grow faster than the US market (23.1% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: TEVA's revenue (0.8% per year) is forecast to grow slower than the US market (9.8% per year).
High Growth Revenue: TEVA's revenue (0.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TEVA's Return on Equity is forecast to be low in 3 years time (18.9%).
How has Teva Pharmaceutical Industries performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TEVA has a large one-off loss of $2.6B impacting its June 30 2020 financial results.
Growing Profit Margin: TEVA became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: TEVA has become profitable over the past 5 years, growing earnings by -27% per year.
Accelerating Growth: TEVA has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: TEVA has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).
Return on Equity
High ROE: TEVA's Return on Equity (-1%) is considered low.
How is Teva Pharmaceutical Industries's financial position?
Financial Position Analysis
Short Term Liabilities: TEVA's short term assets ($12.8B) exceed its short term liabilities ($11.8B).
Long Term Liabilities: TEVA's short term assets ($12.8B) do not cover its long term liabilities ($28.4B).
Debt to Equity History and Analysis
Debt Level: TEVA's debt to equity ratio (176.4%) is considered high.
Reducing Debt: TEVA's debt to equity ratio has increased from 54.2% to 176.4% over the past 5 years.
Debt Coverage: TEVA's debt is not well covered by operating cash flow (5.5%).
Interest Coverage: TEVA's interest payments on its debt are well covered by EBIT (3.4x coverage).
What is Teva Pharmaceutical Industries's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TEVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TEVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TEVA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TEVA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: TEVA is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TEVA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Kare Schultz (59 yo)
Mr. Kare Schultz has been the Chief Executive Officer, President and Director of Teva Pharmaceutical Industries Limited since November 1, 2017. Mr. Schultz is a seasoned veteran in the healthcare industry ...
CEO Compensation Analysis
Compensation vs Market: Kare's total compensation ($USD11.60M) is about average for companies of similar size in the US market ($USD11.35M).
Compensation vs Earnings: Kare's compensation has been consistent with company performance over the past year.
|Executive VP & CFO||0.75yr||US$655.76k||no data|
|Executive Vice President of Global R&D||3.58yrs||US$4.38m||0.0042% |
|Executive Vice President of North America Commercial||2.83yrs||US$3.46m||0.0014% |
|Executive Vice President of International Markets Commercial||2.83yrs||US$3.45m||0.0018% |
|Executive Vice President of Global Operations||0.92yr||no data||0.0020% |
|Senior VP & Chief Accounting Officer||no data||no data||no data|
|Senior Vice President of Investor Relations||no data||no data||no data|
|Executive VP & Chief Legal Officer||3.83yrs||no data||0.00027% |
|Senior VP & Global Compliance Officer||5.25yrs||no data||no data|
|Executive VP||1.67yrs||US$5.25m||0.0023% |
|Executive Vice President of Global Marketing & Portfolio||2.83yrs||no data||0.0019% |
Experienced Management: TEVA's management team is considered experienced (2.8 years average tenure).
|Independent Director||3.17yrs||US$355.76k||0.0023% |
|Independent Chairman of the Board||3.58yrs||US$540.00k||0.025% |
|Independent Director||11.67yrs||US$340.51k||0.18% |
|Independent Director||5yrs||US$355.00k||0.0033% |
|Independent Director||3.17yrs||US$340.00k||0.0023% |
|Independent Director||6.25yrs||US$320.45k||0.0028% |
|Independent Director||5yrs||US$330.00k||0.0031% |
|Independent Director||0.25yr||no data||no data|
|Independent Director||3.17yrs||US$320.00k||0.0023% |
|Independent Director||2.25yrs||US$310.42k||0.0016% |
|Independent Director||no data||no data||no data|
Experienced Board: TEVA's board of directors are considered experienced (3.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Teva Pharmaceutical Industries Limited's company bio, employee growth, exchange listings and data sources
- Name: Teva Pharmaceutical Industries Limited
- Ticker: TEVA
- Exchange: NYSE
- Founded: 1901
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$10.388b
- Shares outstanding: 1.10b
- Website: https://www.tevapharm.com
Number of Employees
- Teva Pharmaceutical Industries Limited
- 5 Basel Street
- Petah Tikva
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|TEVA||NYSE (New York Stock Exchange)||Yes||ADR EACH CNV INTO 1 ORD||US||USD||Feb 1982|
|TEV||DB (Deutsche Boerse AG)||Yes||ADR EACH CNV INTO 1 ORD||DE||EUR||Feb 1982|
|TEVA N||BMV (Bolsa Mexicana de Valores)||Yes||ADR EACH CNV INTO 1 ORD||MX||MXN||Feb 1982|
|TEVA||SWX (SIX Swiss Exchange)||Yes||ADR EACH CNV INTO 1 ORD||CH||CHF||Feb 1982|
|0LER||LSE (London Stock Exchange)||Yes||ADR EACH CNV INTO 1 ORD||GB||USD||Feb 1982|
|TEVA||WBAG (Wiener Boerse AG)||Yes||ADR EACH CNV INTO 1 ORD||AT||EUR||Feb 1982|
|TEVJ.F||OTCPK (Pink Sheets LLC)||Ordinary Shares||US||USD||Jun 1994|
|TEVA||TASE (The Tel-Aviv Stock Exchange)||Ordinary Shares||IL||ILS||Jun 1994|
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, E ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/21 06:12|
|End of Day Share Price||2020/09/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.